20.09

2.33% -0.48

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is traded at $20.09, with a volume of 167.74K. It is down -2.33% in the last 24 hours and down -21.15% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Previous Close:

$20.57

Open:

$20.63

24h Volume:

167.74K

Relative Volume:

0.71

Market Cap:

$409.04M

Revenue:

$71.10M

Net Income/Loss:

$-6.38M

P/E Ratio:

-16.73

EPS:

-1.2009

Net Cash Flow:

$-39.84M

1W Performance:

-14.62%

1M Performance:

-21.15%

6M Performance:

-31.48%

1Y Performance:

-30.91%

1-Day Range:

$19.94

$20.63

1-Week Range:

$19.94

$23.83

52-Week Range:

$19.94

$39.70

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(833) 409-4583

Address

TWO TOWER PLACE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

ASMB's Discussions on Twitter

Compare ASMB vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASMB Assembly Biosciences Inc	20.09	409.04M	71.10M	-6.38M	-39.84M	-1.2009
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-01-26	Initiated	UBS	Buy
Sep-24-25	Initiated	Citizens JMP	Mkt Outperform
Aug-18-25	Resumed	H.C. Wainwright	Buy
Mar-25-25	Initiated	Guggenheim	Buy
Sep-20-24	Upgrade	Jefferies	Hold → Buy
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

Oct 05, 2026

Assembly Biosciences to present ABI-6250 phase 1a data at AASLD By Investing.com - Investing.com South Africa

Oct 05, 2026

Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting - www.marketscreener.com

Oct 05, 2026

Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program - Yahoo Finance

Oct 05, 2026

Assembly Biosciences to present ABI-6250 phase 1a data at AASLD - Investing.com

Oct 05, 2026